Horizon / Plein textes La base de ressources documentaires de l'IRD

IRD

Publications des scientifiques de l'IRD

Ayouba Ahidjo, Touré A., Butel Christelle, Keita Alpha Kabinet, Binetruy F., Sow M. S., Foulongne V., Delaporte Eric, Peeters Martine. (2017). Development of a sensitive and specific serological assay based on Luminex technology for detection of antibodies to Zaire Ebola virus. Journal of Clinical Microbiology, 55 (1), 165-176. ISSN 0095-1137

Accès réservé (Intranet IRD) Document en accès réservé (Intranet IRD)

Lien direct chez l'éditeur doi:10.1128/jcm.01979-16

Titre
Development of a sensitive and specific serological assay based on Luminex technology for detection of antibodies to Zaire Ebola virus
Année de publication2017
Type de documentArticle référencé dans le Web of Science WOS:000391966600021
AuteursAyouba Ahidjo, Touré A., Butel Christelle, Keita Alpha Kabinet, Binetruy F., Sow M. S., Foulongne V., Delaporte Eric, Peeters Martine.
SourceJournal of Clinical Microbiology, 2017, 55 (1), p. 165-176. ISSN 0095-1137
RésuméThe recent Zaire Ebola virus (EBOV) outbreak in West Africa illustrates clearly the need for additional studies with humans and animals to elucidate the ecology of Ebola viruses (EBVs). In this study, we developed a serological assay based on the Luminex technology. Nine recombinant proteins representing different viral regions (nucleoprotein [NP], 40-kDa viral protein [VP40], and glycoprotein [GP]) from four of the five EBV lineages were used. Samples from 94 survivors of the EBOV outbreak in Guinea and negative samples from 108 patients in France were used to calculate test performance for EBOV detection and cross-reaction with other Ebola virus lineages. For EBOV antibody detection, sensitivities of 95.7%, 96.8%, and 92.5% and specificities of 94.4%, 95.4%, and 96.3% for NP, GP, and VP40, respectively, were observed. All EBOV-negative samples that presented a reaction, except for one, interacted with a single antigen, whereas almost all samples from EBOV survivors were simultaneously reactive with NP and GP (90/94) or with NP, GP, and VP40 (87/ 94). Considering as positive for past EBOV infection only samples that reacted with EBOV NP and GP, sensitivity was 95.7% and specificity increased to 99.1%. Comparing results with commercial EBOV NP and GP enzyme-linked immunosorbent assays (ELISAs; Alpha Diagnostic, San Antonio, TX), lower sensitivity (92.5%) and high specificity (100%) were observed with the same positivity criteria. Samples from EBOV survivors cross-reacted with GP from Sudan Ebola virus (GP-SUDV) (81.9%), GP from Bundibugyo Ebola virus (GP-BDBV) (51.1%), GP from Reston Ebola virus (GP-RESTV) (9.6%), VP40-SUDV (76.6%), and VP40-BDBV (38.3%). Overall, we developed a sensitive and specific high-throughput serological assay, and defined an algorithm, for epidemiological surveys with humans.
Plan de classementEntomologie médicale / Parasitologie / Virologie [052] ; Sciences fondamentales / Techniques d'analyse et de recherche [020]
LocalisationFonds IRD [F B010068902]
Identifiant IRDfdi:010068902
Lien permanenthttp://www.documentation.ird.fr/hor/fdi:010068902

Export des données

Disponibilité des documents

Télechargment fichier PDF téléchargeable

Lien sur le Web lien chez l'éditeur

Accès réservé en accès réservé

HAL en libre accès sur HAL


Accès aux documents originaux :

Accès direct

Bureau du chercheur

Site de la documentation

Espace intranet IST (accès réservé)

Suivi des publications IRD (accès réservé)

Mentions légales

Services Horizon

Poser une question

Consulter l'aide en ligne

Déposer une publication (accès réservé)

S'abonner au flux RSS

Voir les tableaux chronologiques et thématiques

Centres de documentation

Bondy

Montpellier (centre IRD)

Montpellier (MSE)

Nouméa

Papeete

Niamey

Ouagadougou

Tunis

La Paz

Quito